265 related articles for article (PubMed ID: 23898124)
21. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Reardon DA; Egorin MJ; Quinn JA; Rich JN; Gururangan S; Vredenburgh JJ; Desjardins A; Sathornsumetee S; Provenzale JM; Herndon JE; Dowell JM; Badruddoja MA; McLendon RE; Lagattuta TF; Kicielinski KP; Dresemann G; Sampson JH; Friedman AH; Salvado AJ; Friedman HS
J Clin Oncol; 2005 Dec; 23(36):9359-68. PubMed ID: 16361636
[TBL] [Abstract][Full Text] [Related]
22. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
Groves MD; Puduvalli VK; Chang SM; Conrad CA; Gilbert MR; Tremont-Lukats IW; Liu TJ; Peterson P; Schiff D; Cloughesy TF; Wen PY; Greenberg H; Abrey LE; DeAngelis LM; Hess KR; Lamborn KR; Prados MD; Yung WK
J Neurooncol; 2007 Feb; 81(3):271-7. PubMed ID: 17031561
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Gabrielson A; Tesfaye AA; Marshall JL; Pishvaian MJ; Smaglo B; Jha R; Dorsch-Vogel K; Wang H; He AR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1073-9. PubMed ID: 26449224
[TBL] [Abstract][Full Text] [Related]
25. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Silvani A; Eoli M; Salmaggi A; Lamperti E; Maccagnano E; Broggi G; Boiardi A
J Neurooncol; 2004 Jan; 66(1-2):203-8. PubMed ID: 15015788
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
[TBL] [Abstract][Full Text] [Related]
28. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.
Kong DS; Lee JI; Kim WS; Son MJ; Lim DH; Kim ST; Park K; Kim JH; Eoh W; Nam DH
Oncol Rep; 2006 Nov; 16(5):1117-21. PubMed ID: 17016602
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide and thalidomide in the treatment of glioblastoma multiforme.
Riva M; Imbesi F; Beghi E; Galli C; Citterio A; Trapani P; Sterzi R; Collice M
Anticancer Res; 2007; 27(2):1067-71. PubMed ID: 17465245
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Reynés G; Martínez-Sales V; Vila V; Balañá C; Pérez-Segura P; Vaz MA; Benavides M; Gallego O; Palomero I; Gil-Gil M; Fleitas T; Reche E
Anticancer Drugs; 2016 Feb; 27(2):133-7. PubMed ID: 26574999
[TBL] [Abstract][Full Text] [Related]
31. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Chevreau C; Le Cesne A; Ray-Coquard I; Italiano A; Cioffi A; Isambert N; Robin YM; Fournier C; Clisant S; Chaigneau L; Bay JO; Bompas E; Gauthier E; Blay JY; Penel N
Cancer; 2013 Jul; 119(14):2639-44. PubMed ID: 23589078
[TBL] [Abstract][Full Text] [Related]
33. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
Groves MD; Puduvalli VK; Gilbert MR; Levin VA; Conrad CA; Liu VH; Hunter K; Meyers C; Hess KR; Alfred Yung WK
Br J Cancer; 2009 Aug; 101(4):615-20. PubMed ID: 19672263
[TBL] [Abstract][Full Text] [Related]
34. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Brandes AA; Stupp R; Hau P; Lacombe D; Gorlia T; Tosoni A; Mirimanoff RO; Kros JM; van den Bent MJ
Eur J Cancer; 2010 Jan; 46(2):348-54. PubMed ID: 19945857
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Reardon DA; Desjardins A; Peters K; Gururangan S; Sampson J; Rich JN; McLendon R; Herndon JE; Marcello J; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
J Neurooncol; 2011 Jun; 103(2):371-9. PubMed ID: 20853132
[TBL] [Abstract][Full Text] [Related]
36. Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma.
Santoni M; Paccapelo A; Burattini L; Onofri A; Cascinu S
Anticancer Res; 2012 Mar; 32(3):1099-101. PubMed ID: 22399639
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
Lee EQ; Kuhn J; Lamborn KR; Abrey L; DeAngelis LM; Lieberman F; Robins HI; Chang SM; Yung WK; Drappatz J; Mehta MP; Levin VA; Aldape K; Dancey JE; Wright JJ; Prados MD; Cloughesy TF; Gilbert MR; Wen PY
Neuro Oncol; 2012 Dec; 14(12):1511-8. PubMed ID: 23099651
[TBL] [Abstract][Full Text] [Related]
39. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Badruddoja MA; Pazzi M; Sanan A; Schroeder K; Kuzma K; Norton T; Scully T; Mahadevan D; Ahmadi MM
Cancer Chemother Pharmacol; 2017 Oct; 80(4):715-721. PubMed ID: 28808777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
